Literature DB >> 15906769

Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats.

Tsunehisa Noto1, Hiroshi Yamada, Takashi Inui, Kayoko Okuyama, Ayako Watanable, Isami Kimura, Masaaki Nagasaki.   

Abstract

Ecabet, an antiulcer drug, is reported to be effective in patients with ulcerative colitis. We investigated the effect of ecabet enema on ulcerative colitis in rats and some mechanisms underlying this effect. In vivo ecabet enema showed a therapeutic effect in the rat ulcerative colitis model induced by dextran sodium sulfate in the drinking water. The amount of ecabet bound to damaged mucosa was higher than that bound to normal mucosa 30 min after intrarectal administration. In vitro ecabet accelerated the restitution of epithelial cells, which was not affected by a TGF-beta antibody. Ecabet inhibited the leukotriene B4 production and 5-lipoxygenase activity in human neutrophils. In conclusion, ecabet enema showed a therapeutic effect in rats with ulcerative colitis. This effect may be attributable to the high binding affinity for damaged mucosa, the acceleration of restitution, and the inhibition of leukotriene B4 production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906769     DOI: 10.1007/s10620-005-2665-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa.

Authors:  T Ichikawa; K Ishihara; H Hayashida; H Hiruma; K Saigenji; K Hotta
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study.

Authors:  T Kono; M Nomura; S Kasai; Y Kohgo
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

4.  Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric mucosal lesions induced by necrotizing agents and gastric mucosal defensive factors in rats.

Authors:  Y Onoda; M Takido; T Magaribuchi; H Tamaki
Journal:  Jpn J Pharmacol       Date:  1990-04

5.  Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.

Authors:  I Kimura; M Kawasaki; S Nagahama; A Matsuda; M Kataoka; Y Kokuba
Journal:  Arzneimittelforschung       Date:  1998-11

6.  Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogs.

Authors:  Y Ito; T Fukushima; Y Sugawara; O Takaiti; S Nakamura
Journal:  J Pharmacobiodyn       Date:  1991-09

7.  Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.

Authors:  R Eliakim; F Karmeli; M Chorev; E Okon; D Rachmilewitz
Journal:  Scand J Gastroenterol       Date:  1992-11       Impact factor: 2.423

8.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

9.  Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastrointestinal mucosal prostanoid production and morphology in rats.

Authors:  M Kinoshita; H Iwasaki; A Yasoshima; H Tamaki
Journal:  Biol Pharm Bull       Date:  1993-12       Impact factor: 2.233

10.  Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers.

Authors:  C Ciacci; S E Lind; D K Podolsky
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  3 in total

1.  Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Michele Biagioli
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.199

2.  Novel topical therapies for distal colitis.

Authors:  Ian Craig Lawrance
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

3.  High affinity of ecabet sodium for inflamed colonic mucosa in ulcerative colitis.

Authors:  Keiichi Mitsuyama; Nobuo Tomiyasu; Junya Masuda; Hiroshi Yamasaki; Osamu Tsuruta; Michio Sata
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.